药物洗脱支架PCI术后双联抗血小板治疗疗程:系统评价与网络Meta分析
该系统评价与网络Meta分析纳入17项随机对照试验(n=46864),比较药物洗脱支架PCI术后短疗程(<6个月)、标准疗程(12个月)与长疗程(>12个月)双联抗血小板治疗的疗效与安全性。主要终点为心源性或非心源性死亡、全因死亡、心肌梗死、支架血栓及所有出血事件。结果显示:与短疗程相比,长疗程DAPT大出血(OR 1.78,95%CI 1.27–2.49)和非心源性死亡(OR 1.63,95%CI 1.03–2.59)更高;标准疗程DAPT任何出血更高(OR 1.39,95%CI 1.01–1.92);其他主要终点无明显差异。亚组分析中,新一代DES患者长疗程DAPT全因死亡高于短疗程(OR 1.99,95%CI 1.04–3.81);ACS患者短疗程与标准疗程疗效和安全性相似。作者结论认为,多数DES术后患者可考虑短疗程DAPT,但最佳疗程需结合个体缺血与出血风险。
要点
- 与短疗程DAPT相比,长疗程DAPT大出血更高(OR 1.78,95%CI 1.27–2.49),非心源性死亡更高(OR 1.63,95%CI 1.03–2.59)。
- 与短疗程DAPT相比,标准疗程(12个月)DAPT任何出血更高(OR 1.39,95%CI 1.01–1.92)。
- 新一代DES患者中,长疗程DAPT全因死亡高于短疗程DAPT(OR 1.99,95%CI 1.04–3.81)。
- ACS患者中,短疗程DAPT与标准疗程DAPT疗效和安全性相似。
- 作者认为,结合直接与间接比较证据,多数DES术后患者可考虑短疗程DAPT,但最佳疗程需结合个体缺血与出血风险。
适用人群与场景
- 接受药物洗脱支架(DES)经皮冠状动脉介入治疗(PCI)后的患者,涵盖所有临床表现类型。
- 亚组包括急性冠脉综合征(ACS)患者及植入新一代DES的患者。
处置流程与药物剂量
- 短疗程DAPT定义为<6个月,标准疗程为12个月,长疗程为>12个月;原文结论中短疗程DAPT具体药物为氯吡格雷。
- 作者认为,结合直接与间接比较证据,多数DES术后患者可考虑短疗程DAPT。
- 作者指出,最佳DAPT疗程应结合个体缺血与出血风险评估。
研究设计与关键结果
- 系统评价与网络Meta分析,纳入17项随机对照试验,共46864例患者。
- 与短疗程DAPT相比,长疗程DAPT大出血更高(OR 1.78,95%CI 1.27–2.49),非心源性死亡更高(OR 1.63,95%CI 1.03–2.59)。
- 与短疗程DAPT相比,标准疗程DAPT任何出血更高(OR 1.39,95%CI 1.01–1.92)。
- 其他主要终点(心源性或非心源性死亡、全因死亡、心肌梗死、支架血栓、所有出血事件中除外上述者)未见明显差异。
- 敏感性分析显示,与短疗程或标准疗程DAPT相比,≥18个月DAPT的非心源性死亡和出血风险进一步增加。
- 亚组分析:新一代DES患者中,长疗程DAPT全因死亡高于短疗程DAPT(OR 1.99,95%CI 1.04–3.81)。
- 亚组分析:ACS患者中,短疗程DAPT与标准疗程DAPT疗效和安全性相似。
- 汇总试验异质性低。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与网络Meta分析。
- 汇总试验异质性低,增加结果解读信心。
- 系统评价注册号:PROSPERO CRD42018099519。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于DES术后患者,选择DAPT疗程时需权衡缺血与出血风险;作者认为多数患者可考虑短疗程DAPT。
- ACS患者中短疗程与标准疗程DAPT疗效和安全性相似,可影响ACS术后DAPT疗程决策。
- 新一代DES患者中长疗程DAPT全因死亡更高,支持在该人群中审慎评估延长DAPT。
- ≥18个月DAPT较短期或标准疗程出血和非心源性死亡风险进一步增加,应避免无明确指征的过长疗程。
指南或共识出处
- 系统评价与网络Meta分析,PROSPERO注册号CRD42018099519,检索截止2018年4月。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the efficacy and safety of standard term (12 months) or long term (>12 months) dual antiplatelet therapy (DAPT) versus short term (<6 months) DAPT after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).
DESIGN: Systematic review and network meta-analysis.
DATA SOURCES: Relevant studies published between June 1983 and April 2018 from Medline, Embase, Cochrane Library for clinical trials, PubMed, Web of Science, ClinicalTrials.gov, and Clinicaltrialsregister.eu.
REVIEW METHODS: Randomised controlled trials comparing two of the three durations of DAPT (short term, standard term, and long term) after PCI with DES were included. The primary study outcomes were cardiac or non-cardiac death, all cause mortality, myocardial infarction, stent thrombosis, and all bleeding events.
RESULTS: 17 studies (n=46 864) were included. Compared with short term DAPT, network meta-analysis showed that long term DAPT resulted in higher rates of major bleeding (odds ratio 1.78, 95% confidence interval 1.27 to 2.49) and non-cardiac death (1.63, 1.03 to 2.59); standard term DAPT was associated with higher rates of any bleeding (1.39, 1.01 to 1.92). No noticeable difference was observed in other primary endpoints. The sensitivity analysis revealed that the risks of non-cardiac death and bleeding were further increased for ≥18 months of DAPT compared with short term or standard term DAPT. In the subgroup analysis, long term DAPT led to higher all cause mortality than short term DAPT in patients implanted with newer-generation DES (1.99, 1.04 to 3.81); short term DAPT presented similar efficacy and safety to standard term DAPT with acute coronary syndrome (ACS) presentation and newer-generation DES placement. The heterogeneity of pooled trials was low, providing more confidence in the interpretation of results.
CONCLUSIONS: In patients with all clinical presentations, compared with short term DAPT (clopidogrel), long term DAPT led to higher rates of major bleeding and non-cardiac death, and standard term DAPT was associated with an increased risk of any bleeding. For patients with ACS, short term DAPT presented similar efficacy and safety with standard term DAPT. For patients implanted with newer-generation DES, long term DAPT resulted in more all cause mortality than short term DAPT. Although the optimal duration of DAPT should take personal ischaemic and bleeding risks into account, this study suggested short term DAPT could be considered for most patients after PCI with DES, combining evidence from both direct and indirect comparisons.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018099519.
参考来源
- Yin SH, Xu P, Wang B, et al. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ. 2019. PMID: 31253632. doi:10.1136/bmj.l2222
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。